| scholarly article | Q13442814 |
| P2093 | author name string | Yuan Chang | |
| Yu Zhu | |||
| Qiang Fu | |||
| Le Xu | |||
| Jiejie Xu | |||
| Huimin An | |||
| Weijuan Zhang | |||
| Weisi Liu | |||
| P2860 | cites work | High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma | Q36373524 |
| Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma | Q36736210 | ||
| Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas | Q36780903 | ||
| How to build and interpret a nomogram for cancer prognosis | Q37103518 | ||
| Understanding the language of Lys36 methylation at histone H3. | Q37672319 | ||
| Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new. | Q37728343 | ||
| What can molecular pathology contribute to the management of renal cell carcinoma? | Q37864528 | ||
| A Systematic Approach to Defining the microRNA Landscape in Metastasis. | Q40841399 | ||
| Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma. | Q43806776 | ||
| Impact of histologic subtype on cancer-specific survival in patients with renal cell carcinoma and tumor thrombus. | Q46026247 | ||
| Prognostic value of diametrically polarized tumor-associated macrophages in renal cell carcinoma | Q46223371 | ||
| Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. | Q51154107 | ||
| Renal-Cell Carcinoma | Q56019528 | ||
| Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma | Q24337664 | ||
| The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSα | Q24339204 | ||
| Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network | Q27852242 | ||
| Comprehensive molecular characterization of clear cell renal cell carcinoma | Q27852374 | ||
| Integrated molecular analysis of clear-cell renal cell carcinoma | Q27852382 | ||
| Histone H3 lysine 36 methyltransferase Hypb/Setd2 is required for embryonic vascular remodeling | Q28587253 | ||
| JmjC-domain-containing proteins and histone demethylation | Q29614517 | ||
| Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes | Q29615757 | ||
| Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma | Q33821055 | ||
| The genetic basis of kidney cancer: a metabolic disease | Q34087148 | ||
| BAP1 loss defines a new class of renal cell carcinoma | Q34280223 | ||
| SETD2-dependent histone H3K36 trimethylation is required for homologous recombination repair and genome stability | Q35188529 | ||
| miR-106b-5p targets tumor suppressor gene SETD2 to inactive its function in clear cell renal cell carcinoma | Q35551941 | ||
| Identification of functional cooperative mutations of SETD2 in human acute leukemia | Q35632973 | ||
| SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair | Q36320349 | ||
| P433 | issue | 45 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e2004 | |
| P577 | publication date | 2015-11-01 | |
| P1433 | published in | Medicine | Q15716652 |
| P1476 | title | Decreased Expression of SETD2 Predicts Unfavorable Prognosis in Patients With Nonmetastatic Clear-Cell Renal Cell Carcinoma | |
| P478 | volume | 94 |
| Q47218884 | Characterizing recurrent and lethal small renal masses in clear cell renal cell carcinoma using recurrent somatic mutations. |
| Q92412551 | Combining molecular and imaging metrics in cancer: radiogenomics |
| Q38752272 | Dual Chromatin and Cytoskeletal Remodeling by SETD2. |
| Q61815553 | Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma |
| Q64107856 | Genetic polymorphisms of histone methyltransferase SETD2 predicts prognosis and chemotherapy response in Chinese acute myeloid leukemia patients |
| Q33913967 | Intratumoral heterogeneity analysis reveals hidden associations between protein expression losses and patient survival in clear cell renal cell carcinoma |
| Q38793244 | Progression inference for somatic mutations in cancer |
| Q92180225 | SET domain containing protein 5 (SETD5) enhances tumor cell invasion and is associated with a poor prognosis in non-small cell lung cancer patients |
| Q47669286 | SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia. |
| Q38698612 | SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis |
| Q59136863 | SETD2 mutations in primary central nervous system tumors |
| Q89510215 | Targeting the Immune system and Epigenetic Landscape of Urological Tumors |
Search more.